Anti-Chlamydia Trachomatis LPS [Clone CL21-335.2.3]

C. trachomatis elementary bodies, L2 serovar

This monoclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.2 - 7.4 with no carrier protein or preservatives added.

Liquid

Antibodies are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody is stable for at least one (1) year at -20°C to -70°C. Store product in appropriate aliquots to avoid multiple freeze-thaw cycles.

Next Day 2-8°C

This antibody recognize LPS of Chlamydia trachomatis serovars A, B, Ba, C, D, E, F, G, H, I, J, K, L1, L2, L3. LPS-specificity confirmed as follows: antibody reactivity is eliminated after treatment of EBs with sodium periodate (which destroys LPS but leaves protein unaltered) but is unaffected by proteinase K treatment of EBs (which destroys protein but leaves carbohydrate unaltered). End users should determine optimal concentrations for their applications.

Chlamydia trachomatis is a significant global health concern and the most frequently reported sexually transmitted bacterial infection (STD) in the United States, responsible for over one million annual cases. This gram-negative bacterium infects the columnar epithelium of the cervix, urethra, and rectum, as well as non-genital sites like the lungs and eyes.

The study and detection of key bacterial components, such as Lipopolysaccharide (LPS), is crucial for diagnostics and research, especially since the infection is often asymptomatic. Untreated C. trachomatis infection can lead to serious complications, including pelvic inflammatory disease (PID), infertility, and ectopic pregnancy in women, and epididymitis and orchitis in men. Researchers and diagnostic developers rely on highly specific tools like an Anti-Chlamydia trachomatis LPS Monoclonal Antibody for accurate analysis and screening.